Comparison of metformin and cyproterone-estrodiol compound effect on hs C-reactive protein and serum androgen levels in patients with poly cystic ovary syndrome

The aim of this study was comparison of the effects of Metformin and Cyproterone-estradiol compound on serum androgens and highly sensitive C-reactive protein levels. Sixty patients with Poly Cystic Ovary Syndrome [PCOS] were enrolled in this study conducted during a period of 16 months from December 2004 to March 2006. Thirty subjects were in each group and treated with Metformin one gram per day or Cyproterone-estradiol compound 21 days monthly and at the beginning and after 3 and 6 months, weight, height, testosterone, dehydroepiandrosterone sulfate [DHEA-S] and hs-CRP levels were measured. Mean age of patients was 23.5 +/- 8.7 years with the range of 15 to 49 years. In both groups significant decreases in DHEA-S levels and in Cyproterone-estradiol compound group a significant decrease in testosterone levels were seen after 6 months, but there were no significant decrease on hs-CRP levels. Comparison of two groups showed that there were no significant differences in the effects of these two drugs on serum testosterone, DHEA-S and hs-CRP levels. In our study the level of hs-CRP at the beginning of treatment were significantly higher in patients who were overweight and obese. Also we found that Cyproterone-estradiol compound causes significant decrease at the level of hs-CRP in overweight and obese patients. The results of this study are different from those of previous studies about beneficial effects of Metformin on hs-CRP levels but are similar to the results of studies that revealed probably obesity and overweight has important role in inducing inflammation and increasing CRP levels

[Evaluation of effective factors in decreased bone density in patient with osteoporosis and osteopenia]

Osteoporosis is the most common metabolic bone disease that characterized by reduced bone strength. The aim of this study was to evaluate the prevalence of effective factors in decreased bone density and secondary causes of osteoporosis. This descriptive cross sectional study was done on 105 patients [76 female and 29 male] suffering from osteoporosis, evaluated in the endocrinology Department of Sina hospital, Tabriz- Iran from March 2003 to March 2006. Past medical history clinical symptoms and biochemical results were of patients. Data analyzed using SPSS-14 and chi square test. Osteoporosis and osteopenia were seen in 55% and 45% of patients with reduced bone density, respectively. Daily calcium intake in patients with less than 400 mg, between 400-1000 mg more than 1000 mg were 63.8%, 31,9%, and 3.4%, respectively. The mean +/- SD of sera calcium and vitamin D level were 9.5 +/- 0.6 mg/dl, 45 +/- 37.1 nmol/l respectively. 61.2% of patients had vitamin D deficiency. 33% of patients had secondary osteoporosis. Among the patient with primary osteoporosis 11.3% afflicted to hyper claciuria. This study showed that decreasing bone density was more prominate in women. The rate of daily calcium intake among patients were low. It is suggested these patients osteoporosis could be prevented by consumption food nutrient rich in calcium and vitamin D supplementation